C094 | BEXOBRUTIDEG (NX-5948), A NOVEL BRUTON’S TYROSINE KINASE DEGRADER, SHOWS HIGH CLINICAL ACTIVITY AND TOLERABLE SAFETY IN AN ONGOING PHASE 1A/B STUDY IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA

Bexobrutideg is a novel, orally administered small molecule degrader that induces removal of wild-type and mutant forms of BTK through ubiquitination by the cereblon E3 ligase complex and subsequent proteasomal degradation. We report clinical outcomes from an ongoing Phase 1a/b trial of bexobrutide...

Descripció completa

Dades bibliogràfiques

Autors principals:	P. Zinzani, D. El-Sharkawi, D. Lewis, A. Pulles, Z. Omer, T. Munir, G. Collins, K. Linton, A. Alencar, M. Gleeson, P. Mckay, S. Huntington, S. Injac, N. Shah
Format:	Artigo
Idioma:	Inglês
Publicat:	Ferrata Storti Foundation 2025-09-01
Col·lecció:	Haematologica
Accés en línia:	https://haematologica.org/article/view/12758
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!